S-095029

S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells[1][2].

Sym025

12352203

C-type Lectin-like Receptors (CTLRs)

Immunology/Inflammation

Cancer-programmed cell death

Cancer

[1]Spreafico A, et al. 1495 A phase 1 multicenter study of the safety and efficacy of the NKG2A targeting antibody S095029 as single agent and in combination with anti-PD1 in patients with advanced malignancies[J]. 2024. |[2]Melander M, et al. Abstract LB220: S095029: A novel clinical-stage Fc-silenced NKG2A-blocking antibody with best-in-class potential[J]. Cancer Research, 2023, 83 (8_Supplement) : LB220-LB220.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991610/

Inhibitory Antibodies

No Development Reported